← Back to all trials
Recruiting
NCT07029581
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Conditions: Lewy Body Dementia Psychosis
Sex: All
Ages: 55 Years – 84 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 180
Sponsor: ACADIA Pharmaceuticals Inc.
Location: ATP Clinical Research Inc. Irvine California
Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Eligibility Criteria
Inclusion Criteria:
* Male or female ≥55 years to \
Source: ClinicalTrials.gov (NCT07029581). StuddyBuddy aggregates publicly available trial information.